Skip to main content
Premium Trial:

Request an Annual Quote

Cofactor Genomics Raises $18M in Series A Round

NEW YORK (GenomeWeb) – Cofactor Genomics announced today that it has raised $18 million through an oversubscribed Series A financing round.

The round was led by Menlo Ventures, with participation from new and existing investors including Data Collective, Ascension Ventures, iSelect, Y Combinator, Wilson Sonsini Goodrich & Rosati, and Stanford. In connection with the round, Menlo Ventures' Mark Siegel, Data Collective's Matt Ocko, and Ascension's John Kuelper have joined Cofactor's board.

Earlier this year, Cofactor launched Pinnacle, an RNA-based oncology assay that analyzes gene fusions and gene expression in patient tumor samples to provide physicians with potential treatment targets. It is the company's first product following a strategic refocusing onto RNA sequencing and software development. Cofactor is currently preparing to commercialize an immuno-oncology assay called Paragon later this year.

"This financing … is enormous validation of the platform that we've built, and reflects excitement for Cofactor's next phase of growth where we intend to package this expertise in discrete applications that can be easily adopted by research labs and clinical practices throughout the nation," Cofactor CEO Jarret Glasscock said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more